14 results on '"Eickhardt‐Dalbøge, Christina Schjellerup"'
Search Results
2. Combination therapy with ruxolitinib and pegylated interferon alfa-2a in newly diagnosed patients with polycythemia vera
3. The gut microbiota in patients with polycythemia vera is distinct from that of healthy controls and varies by treatment
4. Mathematical modelling of stem and progenitor cell dynamics during ruxolitinib treatment of patients with myeloproliferative neoplasms.
5. JAK2V617F drives gut microbiota differences in patients with myeloproliferative neoplasms.
6. Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis.
7. Quality of Life and Symptom Burden of Patients with MPN during Treatment with Hydroxyurea or Pegylated Interferon-alpha2: Results from a Randomized Controlled Trial
8. Clonal haematopoiesis of indeterminate potential and impaired kidney function - A Danish general population study with 11 years follow-up
9. Combination Therapy with Ruxolitinib and Interferon in Newly Diagnosed Patients with Polycythemia Vera
10. Patients with Essential Thrombocythemia Have a Gut Microbiota That Differs from Healthy Controls
11. The Impact of Somatic Mutations upon the Response to Combination Therapy with Ruxolitinib and Interferon in MPN Patients
12. Combination Therapy with Ruxolitinib and Pegylated Interferon-alpha2a in Newly Diagnosed Patients with Polycythemia Vera.
13. Pronounced gut microbiota signatures in patients with JAK2V617F- positive essential thrombocythemia.
14. Clonal haematopoiesis of indeterminate potential and impaired kidney function-A Danish general population study with 11 years follow-up.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.